304 related articles for article (PubMed ID: 29728319)
1. Current status and trends in the diagnostics of AML and MDS.
Shumilov E; Flach J; Kohlmann A; Banz Y; Bonadies N; Fiedler M; Pabst T; Bacher U
Blood Rev; 2018 Nov; 32(6):508-519. PubMed ID: 29728319
[TBL] [Abstract][Full Text] [Related]
2. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
Kohlmann A; Bacher U; Schnittger S; Haferlach T
Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
[TBL] [Abstract][Full Text] [Related]
3. Current concepts and future directions for hemato-oncologic diagnostics.
Flach J; Shumilov E; Joncourt R; Porret N; Novak U; Pabst T; Bacher U
Crit Rev Oncol Hematol; 2020 Jul; 151():102977. PubMed ID: 32446181
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
Shapiro RM; Kim DDH
Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
[TBL] [Abstract][Full Text] [Related]
5. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
6. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
7. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
8. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
9. [Application of Next Generation Sequencing for AML/MDS Diagnosis and Treatment].
Cheng HC; Liu SW; Liu Y; Zhao XF; Li W; Qiu L; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1631-1635. PubMed ID: 29262888
[TBL] [Abstract][Full Text] [Related]
10. Applications of Circulating Tumor DNA in Myelodysplastic Syndromes and Acute Myeloid Leukemia: Promises and Challenges.
Xue Y; Xia X; Liu X; Zheng Y; Gu H; Wang X
Front Biosci (Landmark Ed); 2024 Feb; 29(2):86. PubMed ID: 38420833
[TBL] [Abstract][Full Text] [Related]
11. Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
Tawana K; Drazer MW; Churpek JE
Leukemia; 2018 Jul; 32(7):1482-1492. PubMed ID: 29483711
[TBL] [Abstract][Full Text] [Related]
12. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
Hughes CFM; Gallipoli P; Agarwal R
Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
[TBL] [Abstract][Full Text] [Related]
13. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
14. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Nardi V; Hasserjian RP
Surg Pathol Clin; 2016 Mar; 9(1):143-63. PubMed ID: 26940274
[TBL] [Abstract][Full Text] [Related]
15. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
16. [NGS-based molecular genetics of leukemia-a powerful and decentralized approach].
Dintner S; Schmutz M; Sommer S; Langer A; Hirschbühl K; Claus R; Schmid C; Trepel M; Märkl B
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):155-159. PubMed ID: 37975919
[TBL] [Abstract][Full Text] [Related]
17. Introducing minimal residual disease in acute myeloid leukemia.
Ofran Y; Rowe JM
Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
[TBL] [Abstract][Full Text] [Related]
18. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.
Bacher U; Shumilov E; Flach J; Porret N; Joncourt R; Wiedemann G; Fiedler M; Novak U; Amstutz U; Pabst T
Blood Cancer J; 2018 Nov; 8(11):113. PubMed ID: 30420667
[TBL] [Abstract][Full Text] [Related]
19. Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.
Schulz E; Aplan PD; Freeman SD; Pavletic SZ
Blood Adv; 2023 Aug; 7(16):4381-4394. PubMed ID: 37267435
[TBL] [Abstract][Full Text] [Related]
20. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]